Sugemalimab
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb) . Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research[1].
Product Specifications
CAS Number
2256084-03-2
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sugemalimab.html
Purity
98.3
Solubility
H2O
Smiles
[Sugemalimab]
Molecular Weight
(143.33 kDa)
References & Citations
[1]Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82 (5) :593-599.|[2]Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80 (16_Supplement) : 3260-3260.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC882576-500 1x 500 µL
NKX3.1 (Metastatic Prostate Adenocarcinoma Marker) (NKX3.1/2576), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC403588-100 1x 100 µL
CD95 / FAS / TNFRSF6 (FAS/3588), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
TRC-D446080-1G 1 g
2-(2,4-Difluorophenyl)-3-(1H-1,2,4-triazol-1-yl)-1,2-propanediol
Sign In for Pricing
View Details